Ubikare
PrivateLast Round
VC Round
Jan 28, 2022
Total Funding Raised
$280,000
Momentum Score
25 /100
Company Overview
Ubikare is a health-tech company that provides a software platform, NAIHA (Natural & Artificial Intelligence Health Assistant), and in-home socio-sanitary services for the elderly and dependents.
Sector
Healthcare & Life Sciences
Verticals
Vertical SaaS, Medical AI, Telemedicine, Healthcare Analytics, Clinical Trials
Business Model
B2B
Customer Profile
Subscription SaaS, Government Contracts, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ubikare Comps
Public and private peers based on sector, stage, and business model.
Ubikare Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Jan 28, 2022 | ||||
| Strategic | Sep 21, 2021 | ||||
| Seed | Jul 14, 2020 |
Ubikare Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Mutua Ventures | Strategic |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 14, 2026
Partnered with Vicomtech and Multiverse Computing on Q-CLINIC initiative.
- Apr 14, 2026
Launched Q-CLINIC, applying quantum algorithms to clinical data management.
Ubikare Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Ubikare's valuation, stock price, and market status.